Plus Therapeutics Gains with FDA Orphan Drug Designation Plus Therapeutics (PSTV) Gains 311% with FDA Orphan Drug Designation, Plus Therapeutics a clinical-stage pharmaceutical company specializing in targeted radiotherapeutics, has seen its stock skyrocket by +311.43%. This impressive surge follows the U.S. Food and Drug Administration's (FDA) decision to grant Orphan…